Product
REGN14256
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
A Phase 1/2/3 Adaptive Study to Evaluate the Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Patients Without Risk Factors for Progression to Severe DiseaseStatus: Terminated, Estimated PCD: 2022-06-30